Research Analysts Set Expectations for TSE:FRX Q3 Earnings

Key Points

• Wedbush lowered its Q3 2025 earnings estimate for Fennec Pharmaceuticals to ($0.08) per share, a significant decrease from the previous estimate of $0.55, with a full-year consensus at $0.60.
• Fennec Pharmaceuticals' stock experienced a 4.1% decline, trading at C$11.80, with a market cap of C$328.42 million.
• Insider Southpoint Capital Advisors sold 20,609 shares, reducing their stake by 0.51%, with insiders owning 16.20% of the company's stock overall.

Fennec Pharmaceuticals Inc. (TSE:FRX - Free Report) - Wedbush lowered their Q3 2025 earnings estimates for Fennec Pharmaceuticals in a report issued on Monday, October 13th. Wedbush analyst D. Nierengarten now forecasts that the biopharmaceutical company will post earnings of ($0.08) per share for the quarter, down from their previous estimate of $0.55. The consensus estimate for Fennec Pharmaceuticals' current full-year earnings is $0.60 per share. Wedbush also issued estimates for Fennec Pharmaceuticals' Q4 2025 earnings at ($0.04) EPS, FY2025 earnings at ($0.34) EPS, Q1 2026 earnings at ($0.04) EPS, Q2 2026 earnings at $0.52 EPS, Q3 2026 earnings at $0.06 EPS, Q4 2026 earnings at $0.08 EPS, FY2027 earnings at $0.95 EPS and FY2028 earnings at $2.17 EPS.

Fennec Pharmaceuticals Stock Down 4.1%

Shares of FRX stock opened at C$11.80 on Wednesday. The company's fifty day simple moving average is C$12.25 and its two-hundred day simple moving average is C$10.78. Fennec Pharmaceuticals has a 52 week low of C$5.65 and a 52 week high of C$13.83. The stock has a market cap of C$328.42 million, a P/E ratio of -26.22 and a beta of 2.48. The company has a quick ratio of 10.17, a current ratio of 7.80 and a debt-to-equity ratio of -620.83.

Insider Activity at Fennec Pharmaceuticals

In other news, insider Southpoint Capital Advisors Lp sold 20,609 shares of the stock in a transaction that occurred on Thursday, October 9th. The stock was sold at an average price of C$12.89, for a total transaction of C$265,650.01. Following the completion of the transaction, the insider directly owned 4,010,100 shares in the company, valued at approximately C$51,690,189. This represents a 0.51% decrease in their position. Insiders sold 68,889 shares of company stock valued at $900,406 in the last quarter. 16.20% of the stock is currently owned by insiders.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc is a clinical-stage biotechnology company. It is primarily engaged in research and development activities. The company is developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. Its lead product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin induced hearing loss, or ototoxicity in children.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.